Physical Therapists in Bayport, NY Accepting Medicare
7 Physical Therapists found. Showing 1 - 7
 Alexandria Marie Abel, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 74 Gerritsen Ave, Bayport, NY 11705 Phone: 631-655-7856 |
 Mr. Dean Francis Fox, M.S.P.T Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 307 Gerritsen Ave, Bayport, NY 11705 Phone: 631-363-6323 |
 Jonathan Belmonte Pt Pllc Physical Therapist Medicare: Medicare Enrolled Practice Location: 671 Montauk Hwy, Bayport, NY 11705 Phone: 631-235-4147 |
True Potential Physical Therapy P.c. Physical Therapist Medicare: Medicare Enrolled Practice Location: 899 Montauk Hwy, Bayport, NY 11705 Phone: 516-658-2837 |
Michael Dagro, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 899 Montauk Hwy, Bayport, NY 11705 Phone: 631-823-0600 Fax: 631-823-0602 |
Mrs. Karen Barbara Goercke, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 3 Damaris Ct, Bayport, NY 11705 Phone: 631-472-2482 Fax: 631-472-5419 |
Matthew Botros, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 751 Montauk Hwy, Bayport, NY 11705 Phone: 631-313-8872 |
News Archive
New study shows response to HIV vaccine in 6 weeks
A US study on DNA-based and protein HIV vaccines has shown that an antibody and cellular immune response occurs within six weeks.
Scientists have discovered a protein that could be the key to finding a cure for asthma
Scientists at the University's Department of Pharmacology and the Woolcock Institute of Medical Research have discovered a protein produced in human lung cells that could be the key to finding a cure for asthma.
Johns Hopkins Children's Center receives Gates funding for tuberculosis bacterium tracker
Johns Hopkins Children's Center has received a $946,000 grant from the Bill & Melinda Gates Foundation to design a system that visually tracks the behavior of the tuberculosis bacterium in the body and its response to current and new drug treatments.
Presidio Pharmaceuticals completes Phase 1a clinical trial of PPI-461 in healthy subjects
Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a clinical trial of PPI-461, its lead HCV NS5A inhibitor, in healthy subjects. This first-in-human trial evaluated four single doses of PPI-461, followed by a five-day, once-a-day treatment regimen with PPI-461 at the highest tested dose.
Machine learning helps detect new potential drugs to treat COVID-19
Scientists at the University of California, Riverside, have used machine learning to identify hundreds of new potential drugs that could help treat COVID-19, the disease caused by the novel coronavirus, or SARS-CoV-2.
› Verified 1 days ago
Speech-Language Pathologists
Chiropractors
Physical Therapists
Occupational Therapists
Podiatrists